Free tool
FAERS Monitor: Litfulo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215830 or its brand name (Litfulo, Ritlecitinib Tosylate). Reports on generic versions are filed under their own applications.
Reports
1,963
Serious
398
20% of reports
Hospitalization
106
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective346
- therapeutic product effect incomplete135
- condition aggravated120
- off label use109
- headache91
- alopecia66
- diarrhoea66
- urticaria55
- product dose omission issue51
- pruritus50
- fatigue45
- acne44
- rash44
- nausea40
- dizziness36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 156 |
| 2024 | 722 |
| 2025 | 771 |
| 2026 | 311 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,196 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapeutic product effect incompleteSignal | 135 | 20.4 | 17.3 | 2,471 |
| acneSignal | 44 | 6.2 | 4.6 | 188 |
| condition aggravatedSignal | 120 | 4.2 | 3.6 | 297 |
| alopeciaSignal | 66 | 3.6 | 2.8 | 123 |
| urticariaSignal | 55 | 3.5 | 2.7 | 97 |
| drug ineffectiveSignal | 346 | 2.8 | 2.6 | 429 |
| product dose omission issue | 51 | 1.9 | 1.4 | 20 |
| headache | 91 | 1.6 | 1.3 | 18 |
| pruritus | 50 | 1.4 | 1.1 | 5 |
| off label use | 109 | 1.3 | 1.1 | 9 |
| diarrhoea | 66 | 1.1 | 0.9 | 0 |
| rash | 44 | 1.1 | 0.8 | 0 |
| dizziness | 36 | 0.8 | 0.6 | 2 |
| fatigue | 45 | 0.6 | 0.5 | 11 |
| nausea | 40 | 0.5 | 0.4 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.